These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 24984238)

  • 1. Evaluation of interactions between urokinase plasminogen and inhibitors using molecular dynamic simulation and free-energy calculation.
    Sa R; Fang L; Huang M; Li Q; Wei Y; Wu K
    J Phys Chem A; 2014 Oct; 118(39):9113-9. PubMed ID: 24984238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
    Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
    J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
    Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
    J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of amino-acid mutations on specific interactions between urokinase-type plasminogen activator and its receptor: Ab initio molecular orbital calculations.
    Tsuji S; Kasumi T; Nagase K; Yoshikawa E; Kobayashi H; Kurita N
    J Mol Graph Model; 2011 Aug; 29(8):975-84. PubMed ID: 21605990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.
    Sperl S; Jacob U; Arroyo de Prada N; Stürzebecher J; Wilhelm OG; Bode W; Magdolen V; Huber R; Moroder L
    Proc Natl Acad Sci U S A; 2000 May; 97(10):5113-8. PubMed ID: 10805774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is inhibition process better described with MD(QM/MM) simulations? The case of urokinase type plasminogen activator inhibitors.
    Barbault F; Maurel F
    J Comput Chem; 2012 Mar; 33(6):607-16. PubMed ID: 22241532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines.
    Fish PV; Barber CG; Brown DG; Butt R; Collis MG; Dickinson RP; Henry BT; Horne VA; Huggins JP; King E; O'Gara M; McCleverty D; McIntosh F; Phillips C; Webster R
    J Med Chem; 2007 May; 50(10):2341-51. PubMed ID: 17447747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geometry of GPPE binding to picrate and to the urokinase type plasminogen activator.
    Zesławska E; Stürzebecher J; Oleksyn BJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6212-5. PubMed ID: 17905583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.
    Mackman RL; Katz BA; Breitenbucher JG; Hui HC; Verner E; Luong C; Liu L; Sprengeler PA
    J Med Chem; 2001 Nov; 44(23):3856-71. PubMed ID: 11689072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
    Katz BA; Mackman R; Luong C; Radika K; Martelli A; Sprengeler PA; Wang J; Chan H; Wong L
    Chem Biol; 2000 Apr; 7(4):299-312. PubMed ID: 10779411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.
    Katz BA; Elrod K; Verner E; Mackman RL; Luong C; Shrader WD; Sendzik M; Spencer JR; Sprengeler PA; Kolesnikov A; Tai VW; Hui HC; Breitenbucher JG; Allen D; Janc JW
    J Mol Biol; 2003 May; 329(1):93-120. PubMed ID: 12742021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
    Jankun J; Skrzypczak-Jankun E
    Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
    Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
    Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues.
    Jiang L; Zhao B; Xu P; Sørensen HP; Jensen JK; Christensen A; Hosseini M; Nielsen NC; Jensen KJ; Andreasen PA; Huang M
    Int J Biochem Cell Biol; 2015 May; 62():88-92. PubMed ID: 25744057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
    Nagase K; Kobayashi H; Yoshikawa E; Kurita N
    J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines.
    Barber CG; Dickinson RP; Fish PV
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3227-30. PubMed ID: 15149680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insight into the binding modes and inhibition mechanisms of adamantyl-based 1,3-disubstituted urea inhibitors in the active site of the human soluble epoxide hydrolase.
    Chen H; Zhang Y; Ye C; Feng TT; Han JG
    J Biomol Struct Dyn; 2014; 32(8):1231-47. PubMed ID: 23815795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
    Zhao G; Yuan C; Wind T; Huang Z; Andreasen PA; Huang M
    J Struct Biol; 2007 Oct; 160(1):1-10. PubMed ID: 17692534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA).
    Venkatraj M; Messagie J; Joossens J; Lambeir AM; Haemers A; Van der Veken P; Augustyns K
    Bioorg Med Chem; 2012 Feb; 20(4):1557-68. PubMed ID: 22285569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.